ELUTIA INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ELUT in the last 7 days.
No SEC Form 4 filings for $ELUT in the last 30 days.
See all $ELUT insider activity →Elutia (ELUT) received an $8 million escrow payment from Boston Scientific, completing its third funding milestone. The company now expects to be funded into 2029, covering the first full year of its NXT-41x commercial launch. Elutia anticipates FDA clearance for NXT-41x in the first half of 2027.
Elutia Inc. (ELUT) received $8M from the 2025 sale of its BioEnvelope business, extending its funding into 2029. The company expects FDA clearance for NXT-41x in H1 2027, aiming to turn runway into revenue. This follows a quarter of balance-sheet de-risking and new financing.
Elutia (ELUT) reported Q2 2026 earnings, highlighting $26M in new capital, strategic divestitures, and positive survey data for NXT-41x. The company aims to focus on reconstructive surgery market, valued at $1.5B. NXT-41x clearance is expected in 2027, with commercial launch in 2028. The company is funded through 2028.
Recent ELUT coverage spans corporate actions, earnings and mergers & acquisitions.
Positive funding news removes near‑term financing risk and supports the upcoming NXT‑41x launch.
The cash infusion modestly improves the balance sheet and extends runway, likely providing slight upside pressure.
The new financing strengthens the balance sheet and funds upcoming FDA clearance and product launch, likely supporting short-term upside.
The divestiture removes a revenue‑generating line but adds cash; short‑term price impact likely modestly negative as earnings will lose segment contribution.
Divestiture provides non-dilutive cash and refocuses the pipeline on NXT-41x, with FDA clearance expected in 1H 2027.
AlphAI scores every news story that mentions ELUT with an AI model for sentiment and relevance, and aggregates insider trades from ELUTIA INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Elutia (ELUT) received an $8 million escrow payment from Boston Scientific, completing its third funding milestone. The company now expects to be funded into 2029, covering the first full year of its NXT-41x commercial launch. Elutia anticipates FDA clearance for NXT-41x in the first half of 2027.
2 min readElutia Inc. (ELUT) received $8M from the 2025 sale of its BioEnvelope business, extending its funding into 2029. The company expects FDA clearance for NXT-41x in H1 2027, aiming to turn runway into revenue. This follows a quarter of balance-sheet de-risking and new financing.
2 min readElutia (ELUT) reported Q2 2026 earnings, highlighting $26M in new capital, strategic divestitures, and positive survey data for NXT-41x. The company aims to focus on reconstructive surgery market, valued at $1.5B. NXT-41x clearance is expected in 2027, with commercial launch in 2028. The company is funded through 2028.
2 min readELUTIA INC. (ELUT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Elutia Completes SimpliDerm ® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch ● Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months ● Div
2 min readElutia Inc. (NASDAQ: ELUT) said it completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to $11 million. Proceeds include $8 million at closing plus up to $3 million in contingent milestone payments. Elutia expects FDA clearance of its NXT-41x in H1 2027 and says funding supports operations through 2028 launch.
2 min readElutia Inc. (NASDAQ:ELUT) shares fell after a covering analyst downgraded forecasts. The analyst cut 2026 revenue to $7.5m from $12m and raised expected losses to $0.63 per share from $0.60. Revenue is forecast to decline at a 62% annualized rate to 2026, worse than an industry aggregate 23% growth outlook.
3 min readElutia Inc. (NASDAQ:ELUT) said it secured up to $26M via a credit facility and SimpliDerm asset sale to fund operations through FDA clearance and launch of NXT-41x. Q2 net sales were $2.4M. It reported a $7.6M net loss and $19.9M cash at June 30, 2026. FDA decisions are expected in Q4 2026 (NXT-41) and H1 2027 (NXT-41x).
4 min readELUTIA INC. (ELUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track ● Funded through launch: secured up to $26 mil
6 min readElutia Inc. (Nasdaq: ELUT) said it secured a $15 million growth capital loan from Avenue Capital Group to fund development and commercialization of its NXT-41x antibiotic-eluting biomatrix for plastic and reconstructive surgery. Elutia received $10 million at closing, with a $5 million tranche contingent on FDA 510(k) clearance, expected in H1 2027.
4 min readElutia (Nasdaq: ELUT) reported Q2 2026 results and said it secured up to $26 million in non-equity funding for its NXT-41x program, including a $15 million credit facility and up to $11 million from a SimpliDerm divestiture. Q2 net sales were $2.4M, with a $7.6M net loss. The company cites a 96% surgeon interest survey and expects FDA decisions for NXT-41 in 4Q 2026 and NXT-41x in 1H 2027.
7 min read
